Search results
JD Supra: Better Health Care Newsletter
JD Supra· 21 hours agoFederal officials have capped the cost of insulin at $35 a month. For now, that gives relief only to patients 65 and older covered by Medicare. Big Pharma in recent years has flouted that charitable intent.
Small businesses remain haunted by the specter of inflation
Orange County Register· 1 hour agoMajor U.S. retailers are initiating targeted summer sales to attract customers as the specter of...
As pharmacies disappear nationwide, Oregonians among the hardest hit
OregonLive.com· 4 days agoBrooklyn Pharmacy in Southeast Portland is a throwback to the days of mom-and-pop neighborhood...
Medicare Plan Pay Confusion Could Wreck 2025 Enrollment, Lawsuits Warn | ThinkAdvisor
ThinkAdvisor· 4 days agoMedicare plan agents, brokers, distributors and trade groups are asking the federal courts to block...
...Warns of Anti-Competitive Behavior by Massive Insurance Companies in Medicare Advantage That...
Sierra Sun Times· 4 days agoWashington, D.C. — Last Friday, U.S. Senator Elizabeth Warren (D-Mass.) sent a letter to Chiquita Brooks-LaSure, the Administrator of the Centers for < ...
What Happened to Social Security Under Trump, Biden and 13 Other Presidents
GOBankingRates via Yahoo Finance· 22 hours agoAs people grow older, their incomes decline and their healthcare expenses grow. Before Social...
Arizona opinion: Equitable healthcare access and obesity
Arizona Daily Star· 23 hours agoMillions of Americans suffer from obesity. From friends and family to their own healthcare...
What You Should Know Before Taking Popular Weight Loss Drugs Like Ozempic And Wegovy
Forbes· 5 days agoPopular weight loss drugs like Wegovy and Ozempic that contain the common active ingredient...
Synjardy and cost: Reducing long-term drug costs and more
Medical News Today· 5 days agoSynjardy (empagliflozin/metformin) is a brand-name drug that’s prescribed for type 2 diabetes. The...
RBC maintains Perform rating on Neurocrine Bio shares By Investing.com
Investing.com· 1 day agoOn Thursday, RBC Capital maintained its Sector Perform rating on Neurocrine (NASDAQ:NBIX)...